Inventia Life Science: Raises $25M in Series B Funding

Inventia Life Science Raises $25M in Series B Funding

  • Inventia Life Science, a Sidney, Australia-based world leader in advanced 3D cell cultures for research and clinical purposes, closed a US $25M Series B funding round
  • The round was led by Blackbird Ventures with participation from Skip Capital
  • Inventia has also announced the launch of its US operations with the appointment of Dwayne Dexter as its Director of US Sales
  • Dr. Dexter will be instrumental in growing the pharmaceutical and academic customer base and driving adoption of Inventia’s technology in the US and Canada
  • Founded by CEO Dr. Julio Ribeiro Dr. Aidan O’Mahony, Dr. Cameron Ferris and Peter Arthur in 2013, Inventia is creating tools for advanced biomedical discovery
  • The company is headquartered in Sydney, Australia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

Regulators Strengthen Global Crackdown on Finfluencers

A new collaborative approach targets financial influencers amid rising concerns.Highlights: Financial regulators unite to control finfluencers' market impact.Concerns...

ECB Strengthens Digital Euro Rollout with Standard Setter Agreements

New collaborations aim to facilitate the digital euro's global integration.Highlights: ECB partners with key global standard setters.Agreements aim...

CreditNature Strengthens Nature Restoration Funding Through Everyday Transactions

New partnership enables businesses to support environmental initiatives seamlessly.Highlights: CreditNature teams up with Stabiliti for eco-friendly funding.Businesses can...

FedNow Strengthens Instant Payments Security with New API Tool

New API tool enhances security for immediate digital transactions in the U.S.Highlights: FedNow introduces a new API tool...